These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 24136150)
21. The role of FOXL2, SOX9, and β-catenin expression and DICER1 mutation in differentiating sex cord tumor with annular tubules from other sex cord tumors of the ovary. Onder S; Hurdogan O; Bayram A; Yilmaz I; Sozen H; Yavuz E Virchows Arch; 2021 Aug; 479(2):317-324. PubMed ID: 33566167 [TBL] [Abstract][Full Text] [Related]
22. Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis. Chen J; Wang Y; McMonechy MK; Anglesio MS; Yang W; Senz J; Maines-Bandiera S; Rosner J; Trigo-Gonzalez G; Grace Cheng SW; Kim J; Matzuk MM; Morin GB; Huntsman DG J Pathol; 2015 Oct; 237(2):215-25. PubMed ID: 26033159 [TBL] [Abstract][Full Text] [Related]
23. Testicular Neoplasms With Sex Cord and Stromal Components Harbor a Recurrent Pattern of Chromosomal Gains. Acosta AM; Sholl LM; Maclean F; Kao CS; Ulbright TM Mod Pathol; 2024 Jan; 37(1):100368. PubMed ID: 37871653 [TBL] [Abstract][Full Text] [Related]
24. DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. Karnezis AN; Wang Y; Keul J; Tessier-Cloutier B; Magrill J; Kommoss S; Senz J; Yang W; Proctor L; Schmidt D; Clement PB; Gilks CB; Huntsman DG; Kommoss F Am J Surg Pathol; 2019 May; 43(5):628-638. PubMed ID: 30986800 [TBL] [Abstract][Full Text] [Related]
25. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors. Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933 [TBL] [Abstract][Full Text] [Related]
26. Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Schultz KA; Harris A; Messinger Y; Sencer S; Baldinger S; Dehner LP; Hill DA Fam Cancer; 2016 Jan; 15(1):105-10. PubMed ID: 26289771 [TBL] [Abstract][Full Text] [Related]
27. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs. McCluggage WG; Rivera B; Chong AS; Clarke BA; Schultz KAP; Dehner LP; Tchrakian N; Apellaniz-Ruiz M; Gilks CB; Kommoss F; Stewart CJR; Foulkes WD Am J Surg Pathol; 2023 Apr; 47(4):490-496. PubMed ID: 36583307 [TBL] [Abstract][Full Text] [Related]
28. Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Commonly Exhibits Positivity With Sex Cord Markers FOXL2 and SF-1 but Lacks FOXL2 and DICER1 Mutations. Croce S; de Kock L; Boshari T; Hostein I; Velasco V; Foulkes WD; McCluggage WG Int J Gynecol Pathol; 2016 Jul; 35(4):301-8. PubMed ID: 26598979 [TBL] [Abstract][Full Text] [Related]
29. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. de Kock L; Terzic T; McCluggage WG; Stewart CJR; Shaw P; Foulkes WD; Clarke BA Am J Surg Pathol; 2017 Sep; 41(9):1178-1187. PubMed ID: 28654427 [TBL] [Abstract][Full Text] [Related]
30. Testicular Sertoli cell tumour and potentially testicular Leydig cell tumour are features of Golmard L; Vasta LM; Duflos V; Corsini C; Dubois d'Enghien C; McMaster ML; Harney LA; Carr AG; Ling A; Dijoud F; Gauthier A; Miettinen M; Cost NG; Gauthier-Villars M; Orbach D; Irtan S; Haouy S; Schultz KA; Stoppa-Lyonnet D; Coupier I; Stewart DR; Sirvent N J Med Genet; 2022 Apr; 59(4):346-350. PubMed ID: 33782093 [No Abstract] [Full Text] [Related]
31. Ovarian sex cord-stromal tumours: an update in recent molecular advances. Lim D; Oliva E Pathology; 2018 Feb; 50(2):178-189. PubMed ID: 29275930 [TBL] [Abstract][Full Text] [Related]
33. A complex DICER1 syndrome phenotype associated with a germline pathogenic variant affecting the RNase IIIa domain of DICER1. Pontén E; Frisk S; Taylan F; Vaz R; Wessman S; de Kock L; Pal N; Foulkes WD; Lagerstedt-Robinson K; Nordgren A J Med Genet; 2022 Feb; 59(2):141-146. PubMed ID: 33208384 [TBL] [Abstract][Full Text] [Related]
34. Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome. Klein S; Lee H; Ghahremani S; Kempert P; Ischander M; Teitell MA; Nelson SF; Martinez-Agosto JA J Med Genet; 2014 May; 51(5):294-302. PubMed ID: 24676357 [TBL] [Abstract][Full Text] [Related]
35. Distinct somatic DICER1 hotspot mutations in three metachronous ovarian Sertoli-Leydig cell tumors in a patient with DICER1 syndrome. Garcia A; Desrosiers L; Scollon S; Gruner S; Reuther J; Gandhi I; Patil N; Fuller MY; Dai H; Muzny D; Gibbs RA; Bercaw-Pratt JL; Rao SL; Rainusso N; Fisher KE; Lin FY; Plon SE; Parsons DW; Roy A Cancer Genet; 2022 Apr; 262-263():53-56. PubMed ID: 35026696 [No Abstract] [Full Text] [Related]
36. Lessons from genomic profiling: towards a molecular-based classification of ovarian Sertoli-Leydig cell tumour. Kommoss FKF Histopathology; 2024 Mar; 84(4):712-714. PubMed ID: 38114269 [TBL] [Abstract][Full Text] [Related]
40. Germline mutations of DICER1 in Chinese women with BRCA1/BRCA2-negative familial breast cancer. Cao WM; Gao Y; Yang HJ; Xie SN; Meng XL; Pan ZW; Chen ZH; Huang J; Ye WW; Shao XY; Wang XJ Genet Mol Res; 2014 Dec; 13(4):10754-60. PubMed ID: 25526195 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]